Clinical Trials Available
To view a list of available clinical trials, select a type of cancer below. You will get a general overview of the trial, the trial number, and a link to clinicaltrials.gov for the most complete information.
Our collaboration with Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, offers our patients early access to the latest in leading-edge treatments without having to leave the Twin Cities region.
Request Clinical Trial Information
Breast Cancer: GLSI-21-01
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy
Learn More
Breast Cancer: J2J-MC-JZLH
A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
Learn More
Breast Cancer: GS-US-595-6184
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Learn More
Breast Cancer: D7630C00001
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Learn More
Breast Cancer: JZP598-303
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment
Learn More
Breast Cancer: BNT327-02
A Phase II, multi-site, randomized, open-label clinical trial to evaluate the safety, efficacy, and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)
Learn More
Biliary Cancer: JZP598-302
An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer
Learn More
Cervical Cancer: GOG-3043
A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer
Learn More
Endometrial Cancer: PRO1184-001
Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors
Learn More
Endometrial Cancer: XPORT-EC-042 | GOG 3083
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial Of Selinexor In Maintenance Therapy After Systemic Therapy For Patients With P53 Wild-Type, Advanced Or Recurrent Endometrial Carcinoma
Learn More
Endometrial Cancer: FTH-PIK-201
An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) with Paclitaxel, and a Substudy Evaluating PIKTOR with Paclitaxel plus an Insulin-Suppressing Diet, in Patients with Advanced or Recurrent Endometrial Cancer
Learn More
Fallopian Tube Cancer: GOG-3078
Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab
Learn More
Lung Cancer: PUMA-ALI-4201
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Learn More
Lung Cancer: 849-007
A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Learn More
Lung Cancer: CA245-0004
An open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer
Learn More
Lung Cancer: MCLA-158-CL02
A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Learn More
Lymphoma | Hematologic: CA057-001
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM):Successor-1 (CA057-001)
Learn More
Myelomas Cancer: 64007957MMY2010
64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Learn More
Melanoma Cancer: IDE196-002
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Learn More
Melanoma Cancer: R3767-ONC-22122
A phase 3 study of fixed dose combinations of fianlimab and cemiplimab versus relatlimab and nivolumab in participants with unresectable or metastatic melanoma.
Learn More
Ovarian Cancer: TORL123-002/TRIO057/ENGOT-ov83
A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6
Learn More
Ovarian Cancer: GOG-3078
Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab
Learn More
Ovarian Cancer: VS-6766-301
A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer
Learn More
Ovarian Cancer: PRO1184-001
Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors
Learn More
Ovarian Cancer: CORT125134-557
A Phase 2 Study of Relacorilant in Combination with Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA)(CORT125134-557)
Learn More
Peritoneal Cancer: GOG-3078
Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab
Learn More
Ovarian Cancer: PRO1184-001
Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors
Learn More
Prostate Cancer: ORIC-944-01
An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination with an Androgen Receptor Pathway Inhibitor in Patients with Metastatic Prostate Cancer (ORIC-944-01)
Learn More
|
Solid Tumor: WTX-124x2101 |